论文部分内容阅读
目前研究表明高同型半胱氨酸血症是动脉粥样硬化、糖尿病血管并发症、脑血管病等独立危险因素[1],临床上已观察到多种原因导致高同型半胱氨酸血症:饮食、血压、年龄、体重指数、血脂、血肌酐清除率以及胰岛素、氯贝特、环磷酰胺、性激素等多种药物均可影响半胱氨酸的水平,其中重要的抗高血糖药物二甲双胍对血浆同型半胱氨酸影响也不容忽视[2]。近年来随着对糖耐量低减及代谢综合征的积极干预,二甲双胍改善胰岛素抵抗的作用逐渐得到重视,但二甲双胍对血浆同型半胱氨酸的不良影响可能会制约二甲双胍的普遍应用,本文就二甲双胍对血浆同型半胱氨酸影响的研究进展作以下综述。
The current studies have shown that homocysteinemia is an independent risk factor of atherosclerosis, diabetic vascular complications, cerebrovascular disease [1], clinically observed a variety of causes leading to hyperhomocysteinemia Diet, blood pressure, age, body mass index, blood lipids, serum creatinine clearance and insulin, clofibrate, cyclophosphamide, sex hormones and other drugs can affect the level of cysteine, of which an important anti-hyperglycemic drug metformin The impact on plasma homocysteine can not be ignored [2]. In recent years, with the active intervention of low glucose tolerance and metabolic syndrome, the effect of metformin on improving insulin resistance has gradually been taken seriously. However, the adverse effect of metformin on plasma homocysteine may restrict the universal application of metformin. In this paper, metformin The research progress on plasma homocysteine is reviewed as follows.